We are live on ! Find out more
PDSB icon

PDS Biotechnology

55 hedge funds and large institutions have $9.9M invested in PDS Biotechnology in 2025 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

15% more funds holding

Funds holding: 4855 (+7)

1% more capital invested

Capital invested by funds: $9.81M → $9.9M (+$96K)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

1.85% less ownership

Funds ownership: 18.15%16.3% (-1.8%)

Holders
55
Holders Change
+7
Holders Change %
+14.58%
% of All Funds
0.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
12
Reduced
13
Closed
6
Calls
$234K
Puts
Net Calls
+$234K
Net Calls Change
-$79K

PDSB Hedge Fund Activity: Q2 2025 in Review

55 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2025, worth a combined $9.9M — up 0.98% from $9.81M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PDSB positions and 6 closed out — a net gain of 7 holders — while 12 added to existing stakes and 13 trimmed.

The largest buyer was Vanguard Group, adding an estimated $599K. The largest seller was Armistice Capital, cutting an estimated $2.96M.

  • 55 institutional investors held PDS Biotechnology (PDSB) as of Q2 2025, up from 48 in Q1 2025.
  • Funds reported $9.9M of PDS Biotechnology stock for Q2 2025, up 0.98% quarter-over-quarter.
  • 13 funds opened new PDS Biotechnology positions in Q2 2025 and 6 closed out, a net change of +7 holders.
  • The largest PDS Biotechnology buyer in Q2 2025 was Vanguard Group, an estimated $599K added.
  • The largest PDS Biotechnology seller in Q2 2025 was Armistice Capital, an estimated $2.96M sold.

Based on aggregated 13F filings for Q2 2025.